New biomarker for Alzheimer's disease found via CRISPR technique

October 10, 2018, University of Extremadura
The scientists have found a deficiency in the protein STIM1 in brain tissue from patients with Alzheimer's disease. Its involvement in neurodegenerative processes has been verified thanks to the technique CRISPR/Cas9. Up to now, the effects of a deficiency in this protein critical to sporadic Alzheimer's were not known. Credit: University of Extremadura

The objective of the research, undertaken in the laboratories of the IBPM, is to develop a model for studying Alzheimer's disease (AD) of sporadic origin—in other words, AD that is not due to a hereditary genetic mutation. While Alzheimer's disease of familial or hereditary type is responsible for around 5 percent of all cases, it is thought that 95 percent of incidents are of unknown or sporadic origin.

"In Alzheimer's of family origin, there already exist animal models, because we know which genes are linked to this illness. However, in Alzheimer's disease of unknown origin, to date there are no models that enable us to study how it develops," says Francisco Javier Martin-Romero, one of the authors of the study.

These researchers analysed cultures of damaged from a region called medial frontal gyrus, with clinically confirmed alterations provoked by Alzheimer's. These clinical samples were analysed and compared with healthy tissue from patients of the same age. As a result of this comparative study, the scientists found a deficiency in the protein STIM1 in brain tissue from patients with AD.

"We have been working with this protein for 10 years, but we weren't expecting these results with sporadic Alzheimer's," says Martin-Romero. The next step the researchers took was to observe the involvement of this protein STIM1 in the neurodegeneration of the neuron, and they did so using the genetic editing system CRISPR, known popularly as "genetic cut-and-paste." The researchers applied a strategy to eliminate the expression of the gene STIM1 in the neuroblastoma SH-SY5Y cell line, editing the genome with CRISPR/Cas9 using an in vitro model to examine the phenotype of the neuronal deficient in STIM1.

"We use the CRISPR technique on a regular basis in the Faculty of Sciences at the UEx, as it has the great advantage that the genome remains stable despite the cuts in the DNA. In this specific case, CRISPR silences the gene that permits the expression of the protein STIM1 in the neuron. Thus, we were able to simulate what occurs in the neuron without this protein, and we observed alterations very similar to those seen in tissues with Alzheimer's," the researcher says. Up to now, the effects of a deficiency in this protein critical to sporadic Alzheimer's were not known, and so this research offers a new biomarker for the illness, an indicator of the progression of the neurodegenerative process.

One of the alterations observed due to the deficiency of STIM1 is in the transport of through the plasma membrane of the neurons. "This calcium is necessary for the cell to be fully viable, and an alteration in this process affects its entire physiology, finally causing its death. The cell is unable to halt the transport of calcium, which becomes unregulated and out of control," says Martin-Romero. The investigator says that this transport takes place through calcium ion channels regulated by a voltage. These L-type voltage-gated calcium channels can be blocked using pharmaceuticals based on dihydropyridine. In fact, the researchers were able to halt cell death in vitro using pharmaceuticals based on dihydropyridine because of that blocking action, representing an important new finding in the treatment of Alzheimer's.

The next step for the investigators at the IBPM will be to work with and differentiate them into neurons, first for mice and then for humans, to make development of a model possible. This will allow a description of how the absence of stimulus or reduction in the STIM1 determines cell aging in sporadic Alzheimer's disease.

Explore further: Liver disease drug could help restore cells damaged by Alzheimer's

More information: Carlos Pascual-Caro et al, STIM1 deficiency is linked to Alzheimer's disease and triggers cell death in SH-SY5Y cells by upregulation of L-type voltage-operated Ca2+ entry, Journal of Molecular Medicine (2018). DOI: 10.1007/s00109-018-1677-y

Related Stories

Liver disease drug could help restore cells damaged by Alzheimer's

August 31, 2018
A drug which has been used to treat liver disease for decades could help to restore cells damaged by Alzheimer's, a new study from the University of Sheffield has found.

Researchers identify regulation process of protein linked to bipolar disorder

June 11, 2014
Researchers from Tufts have gained new insight into a protein associated with bipolar disorder. The study, published in the June 3 issue of Science Signaling, reveals that calcium channels in resting neurons activate the ...

Neuroscientists discover roles of gene linked to Alzheimer's

May 31, 2018
People with a gene variant called APOE4 have a higher risk of developing late-onset Alzheimer's disease: APOE4 is three times more common among Alzheimer's patients than it is among the general population. However, little ...

Vitamin C deficiency and mitochondrial dysfunction in Alzheimer's disease

December 4, 2017
Early clinical features of sporadic Alzheimer's disease include alterations in mitochondrial function that appear prior to classical features. Mitochondrial dysfunction increases the production of reactive oxygen species ...

Alzheimer's research—intracellular calcium store malfunction leads to brain hyperactivity

February 9, 2018
Alzheimer´s disease is the key cause of dementia in elderly patients. Those affected develop deficiencies in their abilities to learn, think logically, communicate, and to master the challenges of everyday life. To find ...

Recommended for you

New discoveries predict ability to forecast dementia from single molecule

December 11, 2018
Scientists who recently identified the molecular start of Alzheimer's disease have used that finding to determine that it should be possible to forecast which type of dementia will develop over time—a form of personalized ...

Researchers classify Alzheimer's patients in six subgroups

December 5, 2018
Researchers studying Alzheimer's disease have created an approach to classify patients with Alzheimer's disease, a finding that may open the door for personalized treatments.

Neuroscientists pinpoint genes tied to dementia

December 3, 2018
A UCLA-led research team has identified genetic processes involved in the neurodegeneration that occurs in dementia—an important step on the path toward developing therapies that could slow or halt the course of the disease. ...

Detecting signs of neurodegeneration earlier and more accurately

November 30, 2018
Signs of neurodegenerative diseases, appearing years before the emergence of clinical manifestations, can be detected during the examination of medical samples by means of fluorescence microscopy by using new sensitive and ...

Never-before-seen DNA recombination in the brain linked to Alzheimer's disease

November 21, 2018
Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified gene recombination in neurons that produces thousands of new gene variants within Alzheimer's disease brains. The study, published today ...

New information on the pathological mechanisms of Alzheimer's disease

November 21, 2018
Researchers at the University of Helsinki have discovered a mechanism by which harmful tau protein aggregates are transmitted between neurons. Alongside amyloid plaques, tau aggregates in the brain are a significant factor ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.